New treatment plan for nasopharyngeal cancer after EBV DNA stays detectable
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This Phase 3 trial tests a stronger treatment approach for people with locally advanced nasopharyngeal cancer whose EBV “DNA” (a cancer-related virus signal in blood) does not go away after one cycle of chemotherapy. It may help improve outcomes by changing treatment based on how the cancer responds early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed non-keratinizing nasopharyngeal cancer (WHO type II or III) that is EGFR-positive
- You are 18–70 years old
- Your cancer is stage III to IVA (based on the AJCC 8th edition staging)
- Your blood test showed detectable EBV DNA before treatment, and it is still detectable after the first chemotherapy cycle
- Your health is fairly strong (ECOG score 0–1) and you meet blood counts and organ function limits (liver, kidney, and enough blood cells)
- You can sign consent and will be able to attend visits and blood tests as the schedule requires
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial compares giving radiation alone versus giving radiation at the same time as chemotherapy for nasopharyngeal cancer. It focuses on people whose EBV test becomes undetectable after one cycle of chemotherapy, to see which approach works best and is safest.
This early-phase study tests personalized immune cells (EBV CAR-T or TCR-T) to treat nasopharyngeal cancer that has returned or spread. It aims to help the immune system find and attack the cancer after other treatments have not worked.
This Phase 2 trial studies whether adding camrelizumab (an immune medicine) to stereotactic body radiation (focused, high-precision radiation) helps people with recurrent or metastatic nasopharyngeal cancer. It aims to improve control of the cancer (and may use blood EBV levels to help track response).
This trial studies whether tracking levels of Epstein-Barr virus DNA in your blood can help guide treatment for non-metastatic nasopharyngeal cancer. You would get standard radiation and maybe chemotherapy, with extra blood tests to see how the virus levels change.
This trial tests a “choose the best treatment” approach for people with nasopharyngeal cancer (NPC) that is linked to EBV (a common virus). By matching treatment to your EBV and cancer features, the study aims to improve outcomes while tracking safety.
This trial tests whether a lower dose of radiation can safely treat stage III nasopharyngeal cancer if you have already responded well to initial chemotherapy plus immunotherapy (Camrelizumab). The goal is to reduce side effects while still controlling the cancer.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.